Navigation Links
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
Date:5/6/2013

vs. 4.5 months), an improved median event free survival (5.3 months vs. 2.4 months) and a greater overall response rate (24% vs. 0%) compared to patients with elevated AAG. These results may enable more precise targeting of patient populations who will benefit from ARRY-520.

ARRY-520 is currently advancing in three clinical trials.  Continued positive results in these trials will define a clear path to late stage development:

  • Phase 2 trial in combination with dexamethasone in patients with MM refractory to Revlimid® (lenalidomide), Velcade and dexamethasone therapy. 
  • Dose escalation trial in combination with Velcade plus dexamethasone in patients with relapsed or refractory MM.
  • Investigator-sponsored dose escalation trial in combination with Kyprolis® in patients with relapsed or refractory MM who are refractory or intolerant to Velcade therapy.
  • ARRY-614 – Advances in clinical trials in myelodysplastic syndromes ARRY-614 is a dual p38/Tie2 kinase inhibitor offering a unique mechanism of action for the treatment of myelodysplastic syndromes (MDS). In an initial Phase 1 dose-escalation trial in patients with low or intermediate-1 risk MDS, ARRY-614 achieved a response rate of 38% hematologic improvement at the highest dose evaluated. During the quarter, Array continued to evaluate an optimized formulation of ARRY-614 in a clinical trial with a similar patient population. This Phase 1 dose-escalation trial, currently in an expansion phase after reaching the maximum tolerated dose, has the goal of identifying the recommended dose for future clinical trials. As presented at ASH 2012, this new formulation has demonstrated improved bioavailability and target coverage, including higher peak plasma concentrations and overall exposures, as compared to the original formulation.

    At the end of 2012, the FDA provided guidance on future development for this program, including a disc
    '/>"/>

    SOURCE Array BioPharma
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
    2. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
    3. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
    4. Array BioPharma Announces Proposed Public Offering Of Common Stock
    5. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
    6. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
    7. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
    8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
    9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
    10. Array BioPharma To Present At The Cowen Annual Health Care Conference
    11. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/1/2015)... , April 1, 2015 Valeant Pharmaceuticals International, ... today announced the expiration of the tender offer (the ... to purchase all of the outstanding shares of Salix ... price of $173.00 per share in cash, without interest, ... midnight, Eastern time, on April 1, 2015.  Valeant expects ...
    (Date:4/1/2015)... Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: ... raw materials used in the manufacture of traditional Chinese medicine ... financial results for the three- and twelve-months ended December 31, ... 31,Twelve Months Ended December 31, 2014 , 2013 ... $686,669 , $998,934 $4,043,290 , ...
    (Date:3/31/2015)... March 31, 2015 Neurocrine Biosciences, Inc. (Nasdaq: ... into an exclusive collaboration and licensing agreement for the ... Japan and other select Asian ... Tanabe intends to initially develop NBI-98854 in ... disease and tardive dyskinesia. Neurocrine retains full commercial rights ...
    Breaking Medicine Technology:Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 2Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 3Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 2Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 3Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 4Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 5Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 6Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 7Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 8Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 9Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 10Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 11Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4
    ... Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian,biotechnology company Avexa ... blinded phase which,represents the first 24 week segment ... into the open-label section of the,trial (weeks 24 ... twice a day as part of their daily ...
    ... LAINATE, Italy - July 4, 2007 - Cosmo ... its,phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) ... that is not absorbed when taken in tablet ... delivers the active,ingredient into the colon, bacteria in ...
    Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
    (Date:4/1/2015)... (PRWEB) April 01, 2015 Amada Senior ... living placement counseling, recently opened a new office in Rocky ... partners Tracy and Lee Bissett decided to make the move ... the area after over 20 years of experience in management ... April 2nd. , When asked what makes Amada ...
    (Date:4/1/2015)... 2015 TCS Healthcare Technologies (TCS), a ... care management and population health arenas, is pleased to ... Connect, which is fully integrated with the ACUITY platform. ... 1:30 p.m. ET, will be led by Jeff Frater, ... will explore the feature-rich portal as well as the ...
    (Date:4/1/2015)... April 01, 2015 Enterprise Integration ... Global Edition, a distinguished list and report identifying ... The complete 501 list is currently available on ...     The top ranked MSPs in North America , ... and Africa ,     The top MSPs in ...
    (Date:3/31/2015)... As the demand for optimized mobile content ... a mobile-friendly website online sometime during the month of ... continued commitment to bring the best and most accurate ... the same great fitness information at http://www.chunkfitness.com ... to read while browsing on a mobile device. , ...
    (Date:3/31/2015)... The American College of Traditional Chinese Medicine ... will include interesting workshops, lectures and more. The schedule ... April 6, ACTCM welcomes the newest cohort. The orientation ... Square Campus located at 555 DeHaro St. , Town ... Students will be updated on the upcoming merger with ...
    Breaking Medicine News(10 mins):Health News:Amada Senior Care Expands to Eastern North Carolina 2Health News:TCS Healthcare Technologies Releases Acuity Connect 2Health News:TCS Healthcare Technologies Releases Acuity Connect 3Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 2Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 3Health News:ACTCM Announces April Event Schedule 2
    ... to keep abreast of the most important osteoporosis-related research? ... published by the International Osteoporosis Foundation (IOF) on ... in the preceding three to four months. The journal ... Ego Seeman of the University of Melbourne, Australia. ...
    ... Fla. , May 18 Recognized as ... billion Picture Archiving Communications Systems (PACS) market, and ... Leadership Award for Cardiovascular PACS" (CVPACS), and recognized ... Thinking Systems Corporation develops and markets the industry,s ...
    ... Systems, Inc. (NYSE Amex: ADK ), an Ohio-based ... financial results for its first quarter of 2009. Revenues ... compared to $5,992,542 for the same quarter in 2008, an ... improved occupancy at its assisted living communities, an increase in ...
    ... California to volunteer in their communities INDIANAPOLIS, May ... blanket communities in the U.S. and across the globe as ... and energy to improve the health and well-being of their ... of Service.Last year, more than 20,000 Lilly employees from more ...
    ... 18 Bell Environmental Services (BES) , a ... area, is offering a travel bed bug kit to ... this summer, business travelers and anyone traveling away from ... Bed Bug Kit contains a 6 ounce bed ...
    ... Convene in Boston, July 31-August 2 , , ... play a critical role in providing quality care to their ... Summer Meeting in 2009, dermatology nurses will have the opportunity ... dermatology. DNA,s 5th Annual Summer Meeting: On the Pathway to ...
    Cached Medicine News:Health News:Thinking Systems to Showcase the Company's Upgraded ThinkingPACS(TM) and ThinkingRIS(TM) Solutions 2Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 2Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 3Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 4Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 5Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 6Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 7Health News:AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results 8Health News:Lilly to Celebrate Second Annual Global Day of Service May 20 2Health News:Lilly to Celebrate Second Annual Global Day of Service May 20 3Health News:Travel Bed Bug Kit Available for 2009 Summer Travel Season 2Health News:Set out on the Pathway to Change with the Dermatology Nurses' Association 2Health News:Set out on the Pathway to Change with the Dermatology Nurses' Association 3